TGN 1412Alternative Names: Anti-CD28 monoclonal antibody - TeGenero; CD28-SuperMAB™; TGN-1412
Latest Information Update: 19 Jun 2006
At a glance
- Originator TeGenero
- Mechanism of Action CD28 antigen stimulants; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Apr 2006 Discontinued - Phase-I for Cancer in United Kingdom (unspecified route)
- 16 Mar 2006 Suspended - Phase-I for Cancer in United Kingdom (unspecified route)
- 17 Nov 2003 Preclinical trials in Cancer in Germany (unspecified route)